Earlier this year, the U.S. Food and Drug Administration (FDA) published a safety communication that alerts consumers about an increased risk of diabetic ketoacidosis (DKA) with the use of sodium–glucose cotransporter 2 (SGLT2) inhibitors, including Invokana, Invokamet, Farxiga, Jardiance and others. Diabetic ketoacidosis is a potentially life-threatening complication of diabetes... Read more »

A leading professional organization devoted to the care and treatment of diabetes patients has announced a conference convened to review ketoacidosis as one of a handful of possible SGLT2 inhibitor side effects.   The American Association of Clinical Endocrinologists (AACE) announced plans for the conference on June 29 after receiving questions... Read more »

On June 22, 2015, Health Canada – an entity organized under the Government of Canada to help citizens maintain and improve their health – initiated a safety review of the drugs Farxiga and Invokana, which are both used to help control the blood sugar levels of patients diagnosed with Type... Read more »

The FDA issued a safety communication on May 15 warning of serious Invokana side effects involving ketoacidosis, a condition in which too much of certain kinds of acid (ketones) are found in the blood. The agency noted that several instances of the condition, resulting in hospitalization or emergency room visits,... Read more »